West Pharmaceutical Services, Inc. WST
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
West Pharmaceutical Services, Inc. (WST) Free cash flow
West Pharmaceutical Services, Inc.'s free cash flow for fiscal 2025 was $468.9M, up 69.6% from $276.4M in fiscal 2024. Over the twelve months to 30 June 2026 it was $436.9M. Over the past ten years it has ranged from $49.2M (fiscal 2016) to $468.9M (fiscal 2025) — the current reading is the highest in ten years. West Pharmaceutical Services, Inc. ranks 10th of 55 Medical Instruments & Supplies companies by free cash flow.
Free cash flow, annual
Annual
| Period | Free cash flow | Change |
|---|---|---|
| FY2025 | $468.9M | 69.65% |
| FY2024 | $276.4M | (33.32%) |
| FY2023 | $414.5M | (5.67%) |
| FY2022 | $439.4M | 32.91% |
| FY2021 | $330.6M | 10.90% |
| FY2020 | $298.1M | 23.80% |
| FY2019 | $240.8M | 30.94% |
| FY2018 | $183.9M | 38.79% |
| FY2017 | $132.5M | 169.31% |
| FY2016 | $49.2M | (39.11%) |
Quarterly
| Period | Free cash flow | Change |
|---|---|---|
| Jun 2026 | $80.8M | 71.19% |
| Mar 2026 | $47.2M | (73.03%) |
| Dec 2025 | $175.0M | 30.69% |
| Sep 2025 | $133.9M | 31.40% |
| 42 more quarters | Free account |
Against its own ten years
Free cash flow against peers
| Company | Free cash flow |
|---|---|
| BDX Becton, Dickinson and Company compare | $3.2B |
| MDLN Medline Inc. compare | $2.3B |
| RMD ResMed Inc. compare | $1.6B |
| ALC Alcon compare | $1.6B |
| BAX Baxter International Inc. compare | $815.0M |
| COO The Cooper Companies, Inc. compare | $678.0M |
| WST West Pharmaceutical Services, Inc. | $436.9M |
| RGEN Repligen Corporation compare | $110.3M |
| SOLV Solventum Corporation compare | −$118.0M |
What Free cash flow is
Free Cash Flow tells an investor how much cash a company’s operations generate after paying for its investment in physical and intangible assets.
Operating Cash Flow + Property, Plant, Equipment Change (Net) + Intangible Assets Change (Net)
More on WST
- Revenue
- Net income
- EBITDA
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- The full statement